Urogen Pharma Ltd
URGN21.350USD
+0.830+4.04%
종가 02/06, 16:00（ET）시세는 15분 지연됩니다
998.78M시가총액
손실P/E TTM
자세한 내용은 Urogen Pharma Ltd 회사
UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).
Urogen Pharma Ltd 정보
종목 코드 URGN
회사 이름Urogen Pharma Ltd
상장일May 04, 2017
CEOBarrett (Elizabeth A)
직원 수235
유형Ordinary Share
회계 연도 종료May 04
주소9 Ha'ta'asiya St
도시RA'ANANA
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가Israel
우편 번호4365007
전화97297707601
웹사이트https://www.urogen.com/
종목 코드 URGN
상장일May 04, 2017
CEOBarrett (Elizabeth A)
Urogen Pharma Ltd의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Dr. Arie S. Belldegrun, M.D.
Dr. Arie S. Belldegrun, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
408.69K
--
Ms. Elizabeth A. (Liz) Barrett
Ms. Elizabeth A. (Liz) Barrett
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
326.69K
--
Mr. Jason Drew Smith
Mr. Jason Drew Smith
Chief Compliance Officer, General Counsel, Corporate Secretary
Chief Compliance Officer, General Counsel, Corporate Secretary
43.30K
+1813.00%
Mr. Christopher (Chris) Degnan
Mr. Christopher (Chris) Degnan
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
2.28K
+2280.00%
Ms. Cynthia M. Butitta
Ms. Cynthia M. Butitta
Independent Director
Independent Director
2.00K
+2000.00%
Dr. Stuart Holden, M.D.
Dr. Stuart Holden, M.D.
Independent Director
Independent Director
--
--
Dr. Mark P. Schoenberg, M.D.
Dr. Mark P. Schoenberg, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Vincent Perrone
Mr. Vincent Perrone
Investor Relations
Investor Relations
--
--
Dr. Leana S. Wen, M.D.
Dr. Leana S. Wen, M.D.
Independent Director
Independent Director
--
--
Mr. Daniel G. Wildman
Mr. Daniel G. Wildman
Independent Director
Independent Director
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Dr. Arie S. Belldegrun, M.D.
Dr. Arie S. Belldegrun, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
408.69K
--
Ms. Elizabeth A. (Liz) Barrett
Ms. Elizabeth A. (Liz) Barrett
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
326.69K
--
Mr. Jason Drew Smith
Mr. Jason Drew Smith
Chief Compliance Officer, General Counsel, Corporate Secretary
Chief Compliance Officer, General Counsel, Corporate Secretary
43.30K
+1813.00%
Mr. Christopher (Chris) Degnan
Mr. Christopher (Chris) Degnan
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
2.28K
+2280.00%
Ms. Cynthia M. Butitta
Ms. Cynthia M. Butitta
Independent Director
Independent Director
2.00K
+2000.00%
Dr. Stuart Holden, M.D.
Dr. Stuart Holden, M.D.
Independent Director
Independent Director
--
--
수익 분석
통화: USD마지막 업데이트: Tue, Jan 6
통화: USD마지막 업데이트: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
사업별USD
이름
수익
비율
Jelmyto
25.70M
93.53%
Zusduri
1.78M
6.47%
기업이 아직 관련 데이터를 공개하지 않았습니다.
사업별
지역별
사업별USD
이름
수익
비율
Jelmyto
25.70M
93.53%
Zusduri
1.78M
6.47%
주식 보유 통계
마지막 업데이트: Sat, Feb 7
마지막 업데이트: Sat, Feb 7
주주
주주 유형
주주
주주
비율
RTW Investments L.P.
9.71%
Paradigm BioCapital Advisors LP
9.01%
TD Securities, Inc.
6.82%
Morgan Stanley & Co. LLC
5.25%
Jefferies LLC
4.70%
기타
64.52%
주주
주주
비율
RTW Investments L.P.
9.71%
Paradigm BioCapital Advisors LP
9.01%
TD Securities, Inc.
6.82%
Morgan Stanley & Co. LLC
5.25%
Jefferies LLC
4.70%
기타
64.52%
주주 유형
주주
비율
Hedge Fund
29.37%
Research Firm
22.98%
Investment Advisor
22.01%
Investment Advisor/Hedge Fund
19.50%
Insurance Company
4.14%
Individual Investor
2.09%
Corporation
1.79%
Private Equity
1.47%
Bank and Trust
0.25%
기관 주식 보유
마지막 업데이트: Thu, Jan 1
마지막 업데이트: Thu, Jan 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q4
320
48.56M
103.75%
-13.57M
2025Q3
311
45.66M
97.55%
-6.58M
2025Q2
285
53.00M
114.72%
+5.27M
2025Q1
290
49.25M
108.64%
+1.67M
2024Q4
280
43.94M
103.24%
-1.94M
2024Q3
262
44.13M
104.63%
-2.19M
2024Q2
247
46.02M
111.40%
+11.07M
2024Q1
255
34.96M
99.86%
+5.57M
2023Q4
237
29.16M
94.80%
+4.33M
2023Q3
238
25.93M
86.41%
+2.69M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
RTW Investments L.P.
4.54M
9.71%
--
--
Sep 30, 2025
Paradigm BioCapital Advisors LP
4.22M
9.01%
+1.88M
+80.79%
Sep 30, 2025
TD Securities, Inc.
3.19M
6.82%
--
--
Sep 30, 2025
Morgan Stanley & Co. LLC
2.46M
5.25%
+983.01K
+66.65%
Sep 30, 2025
Jefferies LLC
2.20M
4.7%
--
--
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
2.14M
4.58%
+33.75K
+1.60%
Sep 30, 2025
SilverArc Capital Management, LLC
1.58M
3.37%
-445.20K
-22.01%
Sep 30, 2025
Millennium Management LLC
1.47M
3.14%
+874.71K
+147.25%
Sep 30, 2025
UBS Asset Management Switzerland AG
1.32M
2.82%
--
--
Jan 31, 2025
Acorn Capital Advisors, LLC
1.26M
2.69%
--
--
Sep 30, 2025
더 보기
관련 ETF
마지막 업데이트: Sat, Dec 6
마지막 업데이트: Sat, Dec 6
이름
비율
ARK Israel Innovative Technology ETF
2.09%
Tema Oncology ETF
1.92%
ALPS Medical Breakthroughs ETF
0.39%
Hypatia Women CEO ETF
0.28%
ProShares Ultra Nasdaq Biotechnology
0.16%
iShares Micro-Cap ETF
0.15%
Fidelity Enhanced Small Cap ETF
0.11%
Vanguard US Momentum Factor ETF
0.1%
Invesco Nasdaq Biotechnology ETF
0.09%
iShares Biotechnology ETF
0.07%
더 보기
ARK Israel Innovative Technology ETF
비율2.09%
Tema Oncology ETF
비율1.92%
ALPS Medical Breakthroughs ETF
비율0.39%
Hypatia Women CEO ETF
비율0.28%
ProShares Ultra Nasdaq Biotechnology
비율0.16%
iShares Micro-Cap ETF
비율0.15%
Fidelity Enhanced Small Cap ETF
비율0.11%
Vanguard US Momentum Factor ETF
비율0.1%
Invesco Nasdaq Biotechnology ETF
비율0.09%
iShares Biotechnology ETF
비율0.07%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
배당락일
유형
비율
데이터 없음
날짜
배당락일
유형
비율
데이터 없음
